{"filing":{"accession_number":"0001023024-26-000068","cik":"0001023024","ticker":"ANIP","company_name":"ANI PHARMACEUTICALS INC","form":"8-K","filing_date":"2026-08-07","report_date":"2026-08-07","primary_document":"ani-20260807.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1023024/000102302426000068/ani-20260807.htm"},"events":[{"id":26051,"run_id":23660,"accession_number":"0001023024-26-000068","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.97,"summary":"ANI Pharmaceuticals issued a press release on August 7, 2026 announcing second quarter 2026 financial results, including quarterly net revenues of $266.0 million (25.9% YoY growth), GAAP net income of $24.7 million ($1.05 per diluted share), and adjusted non-GAAP EBITDA of $71.6 million (32.4% YoY growth). The company reaffirmed full-year 2026 guidance and modestly adjusted Cortrophin Gel revenue guidance.","company_name":"ANI PHARMACEUTICALS INC","ticker":"ANIP","filing_date":"2026-08-07","form":"8-K","submitted_at":null,"items":[{"id":27036,"accession_number":"0001023024-26-000068","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"ANI Pharmaceuticals issued a press release on August 7, 2026 announcing second quarter 2026 financial results, including quarterly net revenues of $266.0 million (25.9% YoY growth), GAAP net income of $24.7 million ($1.05 per diluted share), and adjusted non-GAAP EBITDA of $71.6 million (32.4% YoY growth). The filing explicitly states this is Item 2.02 disclosure of financial results with the press release furnished as Exhibit 99.1, which is the standard format for earnings releases.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T03:01:33.254159+00:00","company_name":"","ticker":null,"filing_date":""},{"id":27037,"accession_number":"0001023024-26-000068","item_number":"7.01","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"ANI Pharmaceuticals disclosed second quarter 2026 financial results via press release (Exhibit 99.1), reporting quarterly net revenues of $266.0 million (25.9% YoY growth), GAAP net income of $24.7 million ($1.05 per diluted share), and adjusted non-GAAP EBITDA of $71.6 million (32.4% YoY growth). The company also reaffirmed full-year 2026 guidance and modestly adjusted Cortrophin Gel revenue guidance. This is a standard earnings release disclosure material to investors assessing the company's financial performance and outlook.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T03:01:33.254159+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27036,"accession_number":"0001023024-26-000068","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"ANI Pharmaceuticals issued a press release on August 7, 2026 announcing second quarter 2026 financial results, including quarterly net revenues of $266.0 million (25.9% YoY growth), GAAP net income of $24.7 million ($1.05 per diluted share), and adjusted non-GAAP EBITDA of $71.6 million (32.4% YoY growth). The filing explicitly states this is Item 2.02 disclosure of financial results with the press release furnished as Exhibit 99.1, which is the standard format for earnings releases.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T03:01:33.254159+00:00","company_name":"ANI PHARMACEUTICALS INC","ticker":"ANIP","filing_date":"2026-08-07"},{"id":27037,"accession_number":"0001023024-26-000068","item_number":"7.01","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"ANI Pharmaceuticals disclosed second quarter 2026 financial results via press release (Exhibit 99.1), reporting quarterly net revenues of $266.0 million (25.9% YoY growth), GAAP net income of $24.7 million ($1.05 per diluted share), and adjusted non-GAAP EBITDA of $71.6 million (32.4% YoY growth). The company also reaffirmed full-year 2026 guidance and modestly adjusted Cortrophin Gel revenue guidance. This is a standard earnings release disclosure material to investors assessing the company's financial performance and outlook.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T03:01:33.254159+00:00","company_name":"ANI PHARMACEUTICALS INC","ticker":"ANIP","filing_date":"2026-08-07"}]}